Gardiquimod is an agonist of human toll-like receptor 7 (TLR7), but not human TLR8, although it activates both porcine TLR7 and TLR8. At 0.5 to 2 μg/ml, it enhances the immunosuppressive activity of T regulatory cells. Gardiquimod is effective as a mucosal adjuvant for Norwalk virus-like particles and inhibits infection of macrophages and T cells by HIV-1. It inhibits proliferation and migration while inducing apoptosis in pancreatic cancer cells in vitro.
